These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 16364862

  • 1. A randomized, controlled trial of C0- Vs C2-guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients.
    Mathias HC, Ozalp F, Will MB, Borland W, Payne C, Kerr M, Lockhart J, Murday AJ.
    J Heart Lung Transplant; 2005 Dec; 24(12):2137-43. PubMed ID: 16364862
    [Abstract] [Full Text] [Related]

  • 2. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes.
    Delgado DH, Rao V, Hamel J, Miriuka S, Cusimano RJ, Ross HJ.
    J Heart Lung Transplant; 2005 Sep; 24(9):1343-6. PubMed ID: 16143255
    [Abstract] [Full Text] [Related]

  • 3. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
    Hmiel SP, Canter C, Shepherd R, Lassa-Claxton S, Nadler M.
    Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
    [Abstract] [Full Text] [Related]

  • 4. Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation.
    Barnard JB, Thekkudan J, Richardson S, Bittar MN, Martyszczuck R, Hasan J, Khasati N, Keevil B, Yonan N.
    J Heart Lung Transplant; 2006 May; 25(5):564-8. PubMed ID: 16678036
    [Abstract] [Full Text] [Related]

  • 5. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy.
    Cantarovich M, Besner JG, Barkun JS, Elstein E, Loertscher R.
    Clin Transplant; 1998 Jun; 12(3):243-9. PubMed ID: 9642517
    [Abstract] [Full Text] [Related]

  • 6. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
    Akhlaghi F, Gonzalez L, Trull AK.
    J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
    [Abstract] [Full Text] [Related]

  • 7. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
    Büchler M, Chadban S, Cole E, Midtvedt K, Thervet E, Prestele H, Keown P.
    Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
    [Abstract] [Full Text] [Related]

  • 8. Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation.
    Rodrigo E, Ruiz JC, Angeles de Cos M, Ruiz J, Gago M, Piñera C, Sánchez B, González-Cotorruelo J, Gómez-Alamillo C, Arias M.
    Transplant Proc; 2009 Jan; 41(6):2328-31. PubMed ID: 19715910
    [Abstract] [Full Text] [Related]

  • 9. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of changing from cyclosporine C0 to C2 monitoring in stable recipients following renal transplantation: a prospective cohort study.
    Zhang Y, Zhang XD, Wang Y.
    Transplant Proc; 2011 Dec; 43(10):3697-701. PubMed ID: 22172829
    [Abstract] [Full Text] [Related]

  • 11. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
    Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Hübler M, Abd El Rahman MY, Miera O, Ewert P, Weng Y, Wei H, Krüdewagen B, Hetzer R, Berger F.
    J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566
    [Abstract] [Full Text] [Related]

  • 12. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients.
    Caforio AL, Tona F, Piaserico S, Gambino A, Feltrin G, Fortina AB, Angelini A, Alaibac M, Bontorin M, Calzolari D, Peserico A, Thiene G, Iliceto S, Gerosa G.
    Transpl Int; 2005 Jan; 18(1):116-24. PubMed ID: 15612993
    [Abstract] [Full Text] [Related]

  • 13. Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study.
    Iversen M, Nilsson F, Sipponen J, Eiskjaer H, Mared L, Bergan S, Nyström U, Fagertun HE, Solbu D, Simonsen S.
    J Heart Lung Transplant; 2009 Sep; 28(9):919-26. PubMed ID: 19716045
    [Abstract] [Full Text] [Related]

  • 14. C2 monitoring of cyclosporine in stable renal transplant patients results in lower costs and improved renal function.
    Domínguez J, Fuenzalida D, Norambuena R, Pais E, Cortes Monroy G, Llanos R.
    Transplant Proc; 2005 Apr; 37(3):1583-5. PubMed ID: 15866680
    [Abstract] [Full Text] [Related]

  • 15. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E, Delucchi MA, Cano F, Valdebenito S, Castillo MC, Villegas R.
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [Abstract] [Full Text] [Related]

  • 16. Enhanced clinical utility of de novo cyclosporine C2 monitoring after lung transplantation.
    Morton JM, Aboyoun CL, Malouf MA, Plit ML, Glanville AR.
    J Heart Lung Transplant; 2004 Sep; 23(9):1035-9. PubMed ID: 15454168
    [Abstract] [Full Text] [Related]

  • 17. Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients.
    Davies RA, Veinot JP, Williams K, Haddad H, Baker A, Donaldson J, Pugliese C, Struthers C, Masters RG, Hendry PJ, Mesana T.
    Transplant Proc; 2007 Dec; 39(10):3334-9. PubMed ID: 18089382
    [Abstract] [Full Text] [Related]

  • 18. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: a prospective randomized single-center pilot study.
    Kyllönen LE, Salmela KT.
    Transplantation; 2006 Apr 15; 81(7):1010-5. PubMed ID: 16612277
    [Abstract] [Full Text] [Related]

  • 19. C2 and C0 values for monitoring cyclosporine therapy in stable heart transplant recipients.
    Diciolla F, Scolletta S, Berti L, Maccherini M, Federici D, Bernazzali S, Lisi G, Chiavarelli M.
    Transplant Proc; 2005 Mar 15; 37(2):1355-9. PubMed ID: 15848719
    [Abstract] [Full Text] [Related]

  • 20. Impact of late conversion from C0 to C2 monitoring of microemulsified cyclosporine in pediatric living donor liver transplant recipients.
    Takatsuki M, Chen CL, Chen YS, Wang CC, Lin CC, Yang CH, Yong CC, Liu YW.
    Clin Transplant; 2004 Dec 15; 18(6):694-9. PubMed ID: 15516246
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.